Ensysce™ biosciences

Launching the Next Generation Opioid Analgesics

NASDAQ: ENSC

Investor Presentation April 2026

Disclaimer

Ensysce's PF614 and nafamostat are currently in clinical trial and pre-clinical studies, involving both the TAAP platform and MPAR platform. Accordingly, PF614 and nafamostat have the risks and uncertainties inherent in any drug in trial-phase, which include, but are not limited to, a failure to show sufficient efficacy to obtain FDA approval, the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed herein and the possibility that presently unknown safety risks may occur. The statements made concerning PF614, nafamostat, TAAP and MPAR are subject to the complete set of risks set forth in the Risk Factors disclosure found in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Forward Looking Statements

Statements contained in this presentation that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent Annual Report on Form 10-K. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law

Ensysce Summary

Clinical-stage company – 'Next generation opioids' - disrupting analgesia using transformative trypsin-controlled chemistry.

Targeted therapy areas focus on products with blockbuster potential with **FAST TRACK** and **BREAKTHROUGH THERAPY** designations.

Lead Product near term launch with demonstrated safety and efficacy, **reducing clinical risk** with **shortened development timeline.**

Strong global patent estate

Highly experienced management team - broad biopharma background, from drug development to commercialization.

TAAP™

Anti-abuse chemistry

MPAR®

Overdose protection

Ensysce Battling Dueling Crises: Severe Pain vs Abuse/Overdose

Pain is the Leading Cause of Doctor Visits



35 Million
Americans in severe pain

10 Million
Misuse Opioids



143 Million
Opioid Rx in USA

Severe Pain is **#1 fear** in Cancer Patients

https://drugabusestatistics.org/opioid-epidemic/ | https://www.cnn.com/2022/12/14/health/drug-overdose-deaths-slowing/index.html

How is the Ensysce Solution Different?

TAAP™ & MPAR®: Chemical Safety Switches

TAAP™

Trypsin-Activated Abuse Protection*

MPAR®

Multi-Pill Abuse Resistance: Combination Product for Overdose Protection *

PROTECTIVE	Trypsin **TURNS ON RELEASE.**		**TURNS OFF RELEASE** only with overdose.	SMART
CONTROLLABLE	Chemically engineered to control release.		Trypsin inhibitor and TAAP prodrug.	COMBINATION
ANTI-ABUSE	Reduces abuse.		Platform based on trypsin control of activation and release.	UNIQUE
PERFORMANCE	Improves product delivery.		MPAR® can provide overdose protection to other drug classes.	MULTI-USE

*For mechanism see appendix

The Next Generation of Opioids for Powerful Pain Relief

> **New class of opioid**

> **Low abuse –** Prescriber confidence/reassurance to patients

> **Reduced risk of overdose,** *first time ever*

3400 B.C.

Originally identified

1900s

Pharmaceuticals
Immediate release opioids

1990s



Abuse Deterrent Formulations (ADFs)
Extended-release formulations claimed to reduce abuse and addiction

2020s

TAAP™ and MPAR®
Immediate and extended-release chemistry to deliver pain relief when needed

Market Opportunity – US

US Pain Management Drugs Market *



*Ref: IQVIA 2023 Market Data

LAUNCH STRATEGY

- **Launch PF614** for acute severe pain use to provide superior pain control over limited period of time**.
- **Launch PF614-MPAR** for chronic pain
- **Cross reference** NDAs to support acute/ chronic use for both PF614 and MPAR

** PF614 used for post-surgical pain is anticipated to have four key advantages over traditional opioids: (a) pre-dosing at the start of surgery to reduce pain generation from the beginning vs. chasing pain that is already moderate to severe at the end of surgery, (b) having a longer duration of action to allow patients to stop or transition off opioids before leaving the hospital or clinic and continue using only non-opioid drugs at home, (c) reducing overall opioid use, and (d) potentially reducing overall healthcare costs.

Diversified Pipeline

Neuroscience and Respiratory Diseases

Program	Therapeutic Target	Discovery	Phase 1	Phase 2	Phase 3
PF614	Pain with abuse protection	TAAP-Oxycodone			FDA Fast Track
PF614-MPAR	Pain with overdose protection	TAAP-MPAR-Oxycodone			FDA Breakthrough Therapy
PF329	Pain with abuse protection	TAAP-Hydromorphone			
PF8001	ADHD - Immediate release	TAAP-Dexamphetamine			
PF8026	ADHD - Extended release	TAAP-Dexamphetamine			
PF9001	Opioid Use Disorder	TAAP-Methadone			
Nafamostat*	Infectious diseases				

TAAP™ and MPAR® platforms with 505(b)(2) regulatory development path; *Nafamostat in development for MPAR®, infections and respiratory diseases. ER = Extended Release, IR = Immediate Release

Ensysce™ biosciences

PF614 Strong Efficacy – Pain Management RE-Invented

TAAP OXYCODONE

Fast Track Designation

Grant by FDA January 2018

PF614 – 12 hour pain relief/increased safety

PF614 Clinical Data

PF614 efficiently delivers oxycodone



Longer oxycodone half-life supports BID dosing



* From PF614-101, Phase 1 SAD trial
** From Application 208090Orig1s000 CDER pg 11

Reduced nasal abuse potential



PF614 Clinical Studies

PF614-101: SAD Safety and PK

PF614-102: MAD and Bioequivalence to OxyContin

PF614-103: HAP Nasal PF614 vs crushed oxycodone

PF614-104: HAP oral PF614 vs oxycodone

PF614-201: Efficacy in Cold Pressor Study

PF614-301: Abdominoplasty PF614 vs placebo

Next Steps for PF614

PF614 for Severe Pain

- Strong Efficacy –longer efficacy and increased safety
- Phase 3 Launched

2025/2026	DESCRIPTION	SIGNIFICANCE
Regulatory	Phase 3 Protocol reviewed	**FDA feedback on Pivotal study plans received**
PF614-301	Phase 3 study Abdominoplasty: Post-surgical pain initiated 2025	**Pivotal study leading to NDA***
PF614-302	Open label study Bunionectomy: Post-surgical pain – to initiate 2026	**Study to support safety data base leading to NDA***

*NDA = New Drug Application submitted for approval to the FDA.

PF614 Development Plans in US

- Development Pathway for Acute and Chronic Pain Indications



Bold text: Completed
Non-bold text: Planned studies

Ensysce™ biosciences

PF614-MPAR

Powerful Analgesia + Overdose protection

TAAP Oxycodone combination product

Breakthrough Therapy Designation

Grant by FDA January 2024

PF614-MPAR Pre-Clinical Data

— Blocks Activation of PF614 and Oxycodone Release if Overdosed

Oxycodone levels *without* MPAR®

PF614 without nafamostat



Oxycodone levels *with* MPAR®

PF614 with nafamostat



TAAP + MPAR™: PRECLINICAL DATA

in rats n=4 / dose

PRE-CLINICAL MPAR SUPPORT DATA

- Combination product of PF614 with an ultrapotent trypsin inhibitor, nafamostat
- Taken at prescribed doses there is no change in oxycodone release from PF614
- With increasing dose unit administration, increasing amounts of nafamostat blocks trypsin release of oxycodone and prevents opioid overdose



PF614-MPAR Pain Relief with Overdose Protection

Phase 1 Clinical Study Demonstrating Overdose Protection

PF614 alone no MPAR® overdose protection



PF614 mg

PF614 alone (SAD-MAD studies)

Linear dose increase after each dose

PF614-MPAR 25 mg with MPAR® overdose protection



PF614 (mg) or PF614-MPAR [# dose units]

PF614 + nafamostat (PF614-MPAR study)

MPAR- Reduced activation after two dose units

FDA Breakthrough Therapy Designation

Goal to deliver two doses up to twice daily

Trypsin controlled opioid release

PF614-MPAR Development Plans

Clinical Development for Overdose Protection

2025/2026	OUTCOME	SIGNIFICANCE
PF614-MPAR-102	Continue Phase 1b SAD 100 mg dose followed by MAD	Confirm overdose protection followed by MAD study to support Type B FDA meeting
PF614-MPAR	Meeting held with FDA to discuss development plans	Outline path to commercialization

Bold text: Completed
Non-bold text: Planned studies
OD: Overdose
SAD: Single Ascending dose study
MAD: Multi-Ascending dose Study

Ensysce™ biosciences

TAAP™ and MPAR®

Expanded Opportunities

Drug Development Opportunities with TAAP™

Improving Drug Delivery and Lifecycle Management

TAAP™ MODIFICATION ATTRIBUTES

- Reaches the gastrointestinal tract/epithelial cells intact
- Chemistry controlled GI delivery for 'Immediate' or 'Extended-Release'
- Improves aqueous solubility
- Enhances the drug's permeation through the epithelial lining

OPPORTUNITY

Our TAAP™ platform enables new chemical entity (NCE) solutions that allow us to obtain new patents and extend market positions, revitalize approved medications and repurpose approved medications for the benefit of patients and care givers. *Specifically, Ensysce has used to develop a highly novel product for OUD.*

Possible oral delivery of injectable drugs

Enhance activity of drugs on GI tract

Extend half-life to improve dosing

Ensysce™ biosciences

EXPERIENCED MANAGEMENT

Management Team — Highly Motivated, Experienced Team with Proven Record

D. LYNN KIRKPATRICK, PHD

Chief Executive Officer

- Co-founded 2 start up companies
- Developed three targeted small molecule oncology drugs from discovery to clinic
- Experience in private and public company raising funds from private, public and government sources

BIOMIRA | ONCOTHYREON | Yale University School of Medicine

DAVID HUMPHREY, CPA

Chief Financial Officer

- Extensive experience in entrepreneurial environments
- Multiple equity and debt financing, including IPOs
- Focused on financial infrastructure, internal controls with merger and acquisition strategies

senomyx | ACTIVX Biosciences | pwc

GEOFF BIRKETT

Chief Commercial Officer

- Large pharma leadership experience
- Launched 5 major market-leading brands, including:
  - Nicorette | Prozac | Seroquel | Zomig

Lundbeck | NEKTAR | AstraZeneca | Lilly | INSEAD

LINDA PESTANO, PHD

Chief Development Officer

- Experienced in the design of pre-clinical programs focused on building IND-enabling data packages for lead candidate compounds intended for the treatment or diagnosis of cancer and inflammatory diseases
- PhD in Immunology from Tufts, Postdoctoral Research at Dana Farber, Harvard Medical School

VIRIDIAN | ONCOTHYREON | Tufts University | Roche

WILLIAM K SCHMIDT, PHD

Chief Medical Officer

- Over 25 years of pharma industry experience, with special emphasis on discovery and development of novel analgesic and narcotic antagonist drugs
- Past President of the Eastern Pain Association, affiliate of the American Pain Society

DUPONT | Adolor | CrystalGenomics | UCSF

JEFFREY MILLARD, PHD

Chief Operating Officer

- Industrial experience in CMC (chemistry, manufacturing, and controls)
- 7 IND submissions (CDER, CBER, and IMPDs); directed CMC efforts from discovery, in-licensing to commercial launch
- PhD in Pharmaceutical Sciences from University of Arizona

Arizona | ONCOTHYREON | Cascadian Therapeutics | BIOMIRA

Clinical Advisory Board

Pain, Addiction and Abuse Expertise

DR. LYNN WEBSTER

Dr. Webster has dedicated more than three decades to becoming an expert in the field of pain management

DR. JEFFREY GUDIN

Dr. Gudin is Faculty Dept of Anesthesiology/Pain Management, Univ of Miami, and Co-Editor of Practical Pain Management.

DR. RICHARD DART

Dr. Dart is the Director of the Rocky Mountain Poison and Drug Center and specializes in emergency medicine and toxicology.

DR. WILLIAM SCHMIDT

Over 25 years of pharma industry experience, with special emphasis on discovery/development of novel analgesic and narcotic antagonist drugs

Board of Directors

Business, Finance, Healthcare & Regulatory Expertise

Dr. Lynn Kirkpatrick

Career focused on novel drug discovery and development

Dr. Bob Gower

Seasoned Executive and Entrepreneur

William Chang

Entrepreneur, Realty Company & Movie executive

Steve Martin

Experienced Senior Executive and Chief Financial Officer

Dr. Adam Levin

Academic and clinical orthopedic surgeon at Johns Hopkins Univ.

Cash Resources

NASDAQ: ENSC

As of April 2, 2026

Shares Outstanding	9.3M
Shares Public Float	9.3M
Nasdaq Listed	July 2021
Headquarters	La Jolla, CA

$4.3M **Cash**
as of 12/31/25

$2.0M **Equity Financing**
April 2026

$7.4M **MPAR Grant Funding Available**
Jan 2026 to May 2027



NIH support

2018-2023 - $11 million

2024-2027 - $15 million

Awards to advance overdose protection

Two multi-year awards received to undertake the development of the overdose protection platform **MPAR®** (Multi-Pill Abuse Resistance).

NIDA grant

2019-2024 - $5 million

Award to advance TAAP/MPAR OUD

Multi-year award to undertake the pre-clinical and clinical development of TAAP and MPAR® for treatments of Opioid Use Disorder.

Ensysce Summary

Clinical-stage company – 'Next generation opioids' - disrupting analgesia using transformative trypsin-controlled chemistry.

Targeted therapy areas focus on products with blockbuster potential with FAST TRACK and BREAKTHROUGH THERAPY designation.

Lead Product near term launch with demonstrated safety and efficacy **reducing clinical risk**.

Shortened development timeline with 505(b)(2) regulatory pathway, **de-risked** with **positive clinical data** showing the technology works.

Strong global patent estate

Highly experienced management team - broad biopharma background, from drug development to commercialization.

TAAP™

Anti-abuse chemistry

MPAR®

Overdose protection

Ensysce™ biosciences

Investor Relations

SHANNON DEVINE

MZ North America

203-741-8811

ENSC@mzgroup.us

7946 Ivanhoe Avenue, Suite 201, La Jolla, CA 92037

WWW.ENSYSCE.COM